[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112018003741A2 - composições biofarmacêuticas - Google Patents

composições biofarmacêuticas

Info

Publication number
BR112018003741A2
BR112018003741A2 BR112018003741A BR112018003741A BR112018003741A2 BR 112018003741 A2 BR112018003741 A2 BR 112018003741A2 BR 112018003741 A BR112018003741 A BR 112018003741A BR 112018003741 A BR112018003741 A BR 112018003741A BR 112018003741 A2 BR112018003741 A2 BR 112018003741A2
Authority
BR
Brazil
Prior art keywords
compositions
biopharmaceutical compositions
biopharmaceutical
present disclosure
disclosure relates
Prior art date
Application number
BR112018003741A
Other languages
English (en)
Inventor
Dally Jennifer
Spatara Michelle
A Monck Myrna
B Bam Narendra
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56877084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112018003741(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of BR112018003741A2 publication Critical patent/BR112018003741A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente divulgação refere-se às composições para tratar doenças mediadas por interleucina 5 (il-5) e métodos relacionados.
BR112018003741A 2015-08-24 2016-08-22 composições biofarmacêuticas BR112018003741A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562209000P 2015-08-24 2015-08-24
US201562240131P 2015-10-12 2015-10-12
US201562247906P 2015-10-29 2015-10-29
US201562249497P 2015-11-02 2015-11-02
PCT/IB2016/055012 WO2017033121A1 (en) 2015-08-24 2016-08-22 Biopharmaceutical compositions

Publications (1)

Publication Number Publication Date
BR112018003741A2 true BR112018003741A2 (pt) 2018-09-25

Family

ID=56877084

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018003741A BR112018003741A2 (pt) 2015-08-24 2016-08-22 composições biofarmacêuticas

Country Status (22)

Country Link
US (10) US10870695B2 (pt)
EP (2) EP4056590A1 (pt)
JP (4) JP6821659B2 (pt)
KR (2) KR20240099511A (pt)
CN (5) CN116327922A (pt)
AU (1) AU2016311385C1 (pt)
BR (1) BR112018003741A2 (pt)
CA (1) CA2996088A1 (pt)
CL (1) CL2018000499A1 (pt)
CO (1) CO2018001840A2 (pt)
CR (1) CR20180115A (pt)
DO (1) DOP2018000057A (pt)
EA (1) EA037487B1 (pt)
IL (1) IL257539A (pt)
MA (1) MA42692A (pt)
MX (2) MX2018002319A (pt)
PE (1) PE20181176A1 (pt)
PH (1) PH12018500379A1 (pt)
TW (2) TWI750133B (pt)
UY (1) UY36868A (pt)
WO (1) WO2017033121A1 (pt)
ZA (1) ZA201801158B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4056590A1 (en) * 2015-08-24 2022-09-14 GlaxoSmithKline Intellectual Property (No.2) Limited Biopharmaceutical compositions
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
NZ754606A (en) 2016-12-23 2023-06-30 Cephalon Llc Anti-il-5 antibodies
MX2019014105A (es) * 2017-05-26 2020-02-07 Glaxosmithkline Ip Dev Ltd Composiciones biofarmaceuticas y metodos relacionados.
BR112019025736A2 (pt) * 2017-06-06 2020-06-30 Glaxosmithkline Llc uso de um anticorpo e composições para tratar uma doença e para diminuir uma contagem absoluta de eosinófilo no sangue
JP7307720B2 (ja) 2017-09-29 2023-07-12 江蘇恒瑞医薬股▲ふん▼有限公司 Ｉｌ－５抗体、その抗原結合フラグメント、およびそれらの医薬適用
US11613571B2 (en) 2018-05-23 2023-03-28 Glaxosmithkline Intellectual Property Development Limited Biopharmaceutical compositions comprising antibody variants
CA3134401A1 (en) * 2019-03-29 2020-10-08 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing antibody against il-5 and use thereof
MX2022007464A (es) * 2019-12-18 2022-06-27 Tesaro Inc Composiciones biofarmaceuticas y metodos relacionados.
MX2024003250A (es) * 2021-09-22 2024-05-28 Sonoma Biotherapeutics Inc Marcadores de superficie celular il5ra.

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA93779B (en) 1992-02-06 1993-08-05 Schering Corp Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5.
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US6056957A (en) 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US5693323A (en) 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
NZ301916A (en) 1994-12-23 1999-05-28 Smithkline Beecham Corp Monoclonal antibodies to il-5 for use as antagonists to il-5 related disorders
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
GB9712410D0 (en) 1997-06-14 1997-08-13 Glaxo Group Ltd Peptides and compounds that bind to the il-5 receptor
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
DK1988910T3 (en) 2006-02-28 2018-01-22 Kodiak Sciences Inc ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE-CONTAINING POLYMER CONJUGATES AND PREPARATION thereof
US20100086554A1 (en) 2007-04-30 2010-04-08 Smithkline Beecham Corporation Methods for administering anti-il-5 antibodies
EP2225275A4 (en) 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
EP2615115A3 (en) * 2007-11-30 2014-01-08 Glaxo Group Limited Antigen-binding constructs
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
CA2719786A1 (en) 2008-03-28 2009-10-01 Glaxosmithkline Llc Methods of treatment
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
JP5657224B2 (ja) 2009-08-31 2015-01-21 富士フイルム株式会社 放射線画像検出器の撮像面の設置誤差の程度を判定する方法および装置
FR2958646B1 (fr) 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
RU2012134639A (ru) 2010-01-14 2014-02-20 Санва Кагаку Кенкюсо Ко., Лтд. Фармацевтический препарат для предупреждения и лечения нарушений, сопровождающихся глазным ангиогенезом и/или повышенной проницаемостью сосудов глаза
CN107837395A (zh) 2011-02-09 2018-03-27 葛兰素史密斯克莱有限责任公司 冻干制剂
US20140044727A1 (en) 2011-04-07 2014-02-13 Glaxosmithkline Llc Formulations with reduced viscosity
EA201391488A1 (ru) * 2011-04-07 2014-01-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Композиции со сниженной вязкостью
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
BR112015017307A2 (pt) * 2013-03-14 2017-11-21 Abbvie Inc composições de espécies com baixa acidez e métodos para produção e uso das mesmas
WO2014141149A1 (en) 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations with reduced viscosity
EP2848615A1 (en) 2013-07-03 2015-03-18 Almirall, S.A. New pyrazole derivatives as CRAC channel modulators
EP3052092A2 (en) 2013-10-02 2016-08-10 Vectura Limited Method and apparatus
WO2015112886A2 (en) 2014-01-24 2015-07-30 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
CN106536551B (zh) 2014-02-06 2021-04-16 X4制药(奥地利)有限责任公司 大肠杆菌特异性抗体序列
TW201705961A (zh) 2015-06-11 2017-02-16 阿爾米雷爾有限公司 作為ｊａｋ抑制劑的２－（吡唑并吡啶－３－基）嘧啶衍生物
EP4056590A1 (en) * 2015-08-24 2022-09-14 GlaxoSmithKline Intellectual Property (No.2) Limited Biopharmaceutical compositions

Also Published As

Publication number Publication date
US20220185878A1 (en) 2022-06-16
US20220380452A1 (en) 2022-12-01
US20240294630A1 (en) 2024-09-05
MA42692A (fr) 2018-07-04
CR20180115A (es) 2018-04-12
TWI750133B (zh) 2021-12-21
US20210340246A1 (en) 2021-11-04
MX2024001617A (es) 2024-03-06
DOP2018000057A (es) 2018-03-15
TWI780988B (zh) 2022-10-11
CN116327923A (zh) 2023-06-27
US20240294628A1 (en) 2024-09-05
EP3341409A1 (en) 2018-07-04
JP7463070B2 (ja) 2024-04-08
US20210332125A1 (en) 2021-10-28
MX2018002319A (es) 2018-04-11
TW202233238A (zh) 2022-09-01
PH12018500379A1 (en) 2018-09-03
AU2016311385B2 (en) 2019-05-09
JP6821659B2 (ja) 2021-01-27
US20210340247A1 (en) 2021-11-04
US11299541B2 (en) 2022-04-12
CL2018000499A1 (es) 2018-07-06
TW201722473A (zh) 2017-07-01
AU2016311385C1 (en) 2019-08-22
JP2022023049A (ja) 2022-02-07
UY36868A (es) 2017-03-31
CN116327921A (zh) 2023-06-27
CN116474091A (zh) 2023-07-25
CO2018001840A2 (es) 2018-05-31
US11274148B2 (en) 2022-03-15
CN108137683A (zh) 2018-06-08
JP2024123040A (ja) 2024-09-10
EA037487B1 (ru) 2021-04-02
US11459384B2 (en) 2022-10-04
US20180251539A1 (en) 2018-09-06
ZA201801158B (en) 2019-08-28
JP2018526369A (ja) 2018-09-13
KR20240099511A (ko) 2024-06-28
US20240294629A1 (en) 2024-09-05
US20200199219A1 (en) 2020-06-25
US10870695B2 (en) 2020-12-22
EA201890572A1 (ru) 2018-10-31
JP2020033351A (ja) 2020-03-05
EP4056590A1 (en) 2022-09-14
KR20180037275A (ko) 2018-04-11
IL257539A (en) 2018-04-30
CA2996088A1 (en) 2017-03-02
PE20181176A1 (es) 2018-07-20
WO2017033121A1 (en) 2017-03-02
CN116327922A (zh) 2023-06-27
AU2016311385A1 (en) 2018-03-15
US11286298B2 (en) 2022-03-29

Similar Documents

Publication Publication Date Title
BR112018003741A2 (pt) composições biofarmacêuticas
BR112018013065A2 (pt) composições e métodos para o tratamento de hemoglobinopatias
BR112017025004A2 (pt) composições compreendendo cepas bacterianas
BR112018010464A8 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
BR112019012342A2 (pt) anticorpos il-11
BR112018009706A8 (pt) composições compreendendo cepas bacterianas
BR112018009213A2 (pt) composições compreendendo cepas bacterianas
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
BR112017024123A2 (pt) construtos de expressão e métodos de manipulação por engenharia genética de levedura metilotrófica
EA201691582A1 (ru) Новые фармацевтические препараты
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
TW201613893A (en) Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
PH12018500659A1 (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
BR112018012304A2 (pt) composições e métodos para diminuir expressão de tau
BR112018003526A2 (pt) métodos de tratamento de doenças inflamatórias
CO2017001212A2 (es) Moléculas que tienen ciertas utilidades pesticidas y productos intermediarios, composiciones y procesos relacionados con las mismas
BR112017013498A2 (pt) composições de inibidor de nitrificação e métodos para a preparação das mesmas
BR112018003800A2 (pt) derivados de 1,7-diaril-1,6-heptadieno-3,5-diona, processo para a sua produção e utilização
CL2017000312A1 (es) Elección de microarn como diana para trastornos metabólicos
BR112016030129A2 (pt) Composição, artigo moldado por injeção e processo para produzir um artigo moldado por injeção
BR112017028448A2 (pt) análogos de cisteamina resistentes a ado e usos dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]